medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2022, Number 3

<< Back Next >>

An Med Asoc Med Hosp ABC 2022; 67 (3)

Olfatory dysfunction in COVID-19

Grajeda EE, Parra PE, Peralta CD

Language: Spanish
References: 55
Page: 210-215
PDF size: 232.31 Kb.


ABSTRACT

The current COVID-19 pandemic has caused more than 5.5 million deaths worldwide. It has been reported that 50-85% of patients infected with SARS-CoV-2 present olfactory dysfunction, mainly anosmia and hyposmia. In fact, many patients present olfactory dysfunction as the only clinical manifestation or even as the initial symptom. The association between COVID-19 and olfactory dysfunction has been documented, since particles of the virus have been isolated from the nasal cavity of patients with the disease. However, the pathophysiology of olfactory dysfunction is not yet well described. Therefore, the objective of this study is to review the current literature on olfactory manifestations, physiopathological mechanisms on the nasal cavity, its structures, recommendations on treatment and future consequences.


REFERENCES

  1. World Health Organization [Internet]. Weekly Epidemiological Update. Ed 75. [Revisado 20 Enero 2022]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

  2. Graves JA, Baig K, Buntin M. The financial effects and consequences of COVID-19: a gathering storm. JAMA. 2021; 326 (19): 1909-1910.

  3. Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet? Eur Rev Med Pharmacol Sci. 2020; 24 (5): 2781-2783.

  4. Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M et al. COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm. 2021; 18 (3): 754-771.

  5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382 (18): 1708-1720.

  6. Cheong J, Bartell N, Peeraphatdit T, Mosli M, Al-Judaibi B. Gastrointestinal and liver manifestations of COVID-19. Saudi J Gastroenterol. 2020; 26 (5): 226-232.

  7. Gottlieb M, Long B. Dermatologic manifestations and complications of COVID-19. Am J Emerg Med. 2020; 38 (9): 1715-1721.

  8. Liotta EM, Batra A, Clark JR, Shlobin NA, Hoffman SC, Orban ZS et al. Frequent neurologic manifestations and encephalopathy-associated morbidity in Covid-19 patients. Ann Clin Transl Neurol. 2020; 7 (11): 2221-2230.

  9. Marchese-Ragona R, Restivo DA, De Corso E, Vianello A, Nicolai P, Ottaviano G. Loss of smell in COVID-19 patients: a critical review with emphasis on the use of olfactory tests. Acta Otorhinolaryngol Ital. 2020; 40 (4): 241-247.

  10. Mercante G, Ferreli F, De Virgilio A, Gaino F, Di Bari M, Colombo G et al. Prevalence of taste and smell dysfunction in coronavirus disease 2019. JAMA Otolaryngol Head Neck Surg. 2020; 146 (8): 723-728.

  11. Hwang CS. Olfactory neuropathy in severe acute respiratory syndrome: report of a case. Acta Neurol Taiwan. 2006; 15 (1): 26-28.

  12. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope. 2020; 130 (7): 1787.

  13. Li W, Li M, Ou G. COVID-19, cilia, and smell. FEBS J. 2020; 287 (17): 3672-3676.

  14. Dubé M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ. Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. J Virol. 2018; 92 (17): e00404-18.

  15. Chen M, Shen W, Rowan NR, Kulaga H, Hillel A, Ramanathan M Jr et al. Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J. 2020; 56 (3): 2001948.

  16. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020; 382 (12): 1177-1179.

  17. De Melo GD, Lazarini F, Levallois S, Hautefort C, Michel V, Larrous F et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. 2021; 13 (596): eabf8396.

  18. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008; 82 (15): 7264-7275.

  19. Miwa T, Ikeda K, Ishibashi T, Kobayashi M, Kondo K, Matsuwaki Y et al. Clinical practice guidelines for the management of olfactory dysfunction - Secondary publication. Auris Nasus Larynx. 2019; 46 (5): 653-662.

  20. Schwartz JS, Tajudeen BA, Kennedy DW. Diseases of the nasal cavity. Handb Clin Neurol. 2019; 164: 285-302. doi: 10.1016/B978-0-444-63855-7.00018-6.

  21. Imamura F, Hasegawa-Ishii S. Environmental toxicants-induced immune responses in the olfactory mucosa. Front Immunol. 2016; 7: 475.

  22. Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer on viral-associated olfactory loss in the era of COVID-19. Int Forum Allergy Rhinol. 2020; 10 (7): 814-820.

  23. Wu D, Wang VY, Chen YH, Ku CH, Wang PC. The prevalence of olfactory and gustatory dysfunction in covid-19: a systematic review. Auris Nasus Larynx. 2021; S0385-8146(21)00200-5.

  24. Heidari F, Karimi E, Firouzifar M, Khamushian P, Ansari R, Mohammadi Ardehali M et al. Anosmia as a prominent symptom of COVID-19 infection. Rhinology. 2020; 58 (3): 302-303.

  25. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020; 277 (8): 2251-2261.

  26. Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V et al. Features of anosmia in COVID-19. Med Mal Infect. 2020; 50 (5): 436-439.

  27. Eliezer M, Hamel AL, Houdart E, Herman P, Housset J, Jourdaine C et al. Loss of smell in patients with COVID-19: MRI data reveal a transient edema of the olfactory clefts. Neurology. 2020; 95 (23): e3145-e3152.

  28. Yamagishi M, Fujiwara M, Nakamura H. Olfactory mucosal findings and clinical course in patients with olfactory disorders following upper respiratory viral infection. Rhinology. 1994; 32 (3): 113-118.

  29. Kabbani N, Olds JL. Does COVID19 Infect the Brain? If so, smokers might be at a higher risk. Mol Pharmacol. 2020; 97 (5): 351-353.

  30. Daramola OO, Becker SS. An algorithmic approach to the evaluation and treatment of olfactory disorders. Curr Opin Otolaryngol Head Neck Surg. 2015; 23 (1): 8-14.

  31. Harless L, Liang J. Pharmacologic treatment for postviral olfactory dysfunction: a systematic review. Int Forum Allergy Rhinol. 2016; 6 (7): 760-767.

  32. Scangas GA, Bleier BS. Anosmia: differential diagnosis, evaluation, and management. Am J Rhinol Allergy. 2017; 31 (1): 3-7.

  33. British Association of Otorhinolaryngology - Head and Neck Surgery. [Internet]. Loss of sense of smell as marker of COVID-19 infection. Available in: https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf

  34. Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy. 2020; 75 (10): 2440-2444.

  35. Abdelalim AA, Mohamady AA, Elsayed RA, Elawady MA, Ghallab AF. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: a randomized controlled trial. Am J Otolaryngol. 2021; 42 (2): 102884.

  36. Hopkins C, Alanin M, Philpott C, Harries P, Whitcroft K, Qureishi A et al. Management of new onset loss of sense of smell during the COVID-19 pandemic - BRS Consensus Guidelines. Clin Otolaryngol. 2021; 46 (1): 16-22.

  37. Patel ZM, Wise SK, DelGaudio JM. Randomized controlled trial demonstrating cost-effective method of olfactory training in clinical practice: essential oils at uncon- trolled concentration. Laryngoscope Investig Otolaryngol. 2017; 2 (2): 53-56.

  38. Konstantinidis I, Tsakiropoulou E, Constantinidis J. Long term effects of olfactory training in patients with post-infectious olfactory loss. Rhinology. 2016; 54 (2): 170-175.

  39. Denis F, Septans AL, Periers L, Maillard JM, Legoff F, Gurden H et al. Olfactory training and visual stimulation assisted by a web application for patients with persistent olfactory dysfunction after SARS-CoV-2 infection: observational study [published correction appears in J Med Internet Res. 2021; 23 (7): e32120]. J Med Internet Res. 2021; 23 (5): e29583.

  40. Nguyen TP, Patel ZM. Budesonide irrigation with olfactory training improves outcomes compared with olfactory training alone in patients with olfactory loss. Int Forum Allergy Rhinol. 2018; 8 (9): 977-981.

  41. Hummel T, Whitcroft KL, Rueter G, Haehner A. Intranasal vitamin A is beneficial in post-infectious olfactory loss. Eur Arch Otorhinolaryngol. 2017; 274 (7): 2819-2825.

  42. Kanjanaumporn J, Aeumjaturapat S, Snidvongs K, Seresirikachorn K, Chusakul S. Smell and taste dysfunction in patients with SARS-CoV-2 infection: a review of epidemiology, pathogenesis, prognosis, and treatment options. Asian Pac J Allergy Immunol. 2020; 38 (2): 69-77.

  43. Kaye R, Chang CWD, Kazahaya K, Brereton J, Denneny JC 3rd. COVID-19 anosmia reporting tool: initial findings. Otolaryngol Head Neck Surg. 2020; 163 (1): 132-134.

  44. Sedaghat AR, Gengler I, Speth MM. Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance. Otolaryngol Head Neck Surg. 2020; 163 (1): 12-15.

  45. Printza A, Constantinidis J. The role of self-reported smell and taste disorders in suspected COVID-19. Eur Arch Otorhinolaryngol. 2020; 277 (9): 2625-2630.

  46. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021; 147 (2): 545-557.e9.

  47. Jain A, Pandey AK, Kaur J, Kumar L, Singh M, Das S et al. Is there a correlation between viral load and olfactory & taste dysfunction in COVID-19 patients? Am J Otolaryngol. 2021; 42 (3): 102911.

  48. Jafari A, de Lima Xavier L, Bernstein JD, Simonyan K, Bleier BS. Association of sinonasal inflammation with functional brain connectivity. JAMA Otolaryngol Head Neck Surg. 2021; 147 (6): 534-543.

  49. Rowan NR, Schlosser RJ, Storck KA, Ganjaei KG, Soler ZM. The impact of medical therapy on cognitive dysfunction in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2019; 9 (7): 738-745.

  50. D'Ascanio L, Pandolfini M, Cingolani C, Latini G, Gradoni P, Capalbo M et al. Olfactory dysfunction in COVID-19 patients: prevalence and prognosis for recovering sense of smell. Otolaryngol Head Neck Surg. 2021; 164 (1): 82-86.

  51. Hascup ER, Hascup KN. Does SARS-CoV-2 infection cause chronic neurological complications? GeroScience. 2020; 42 (4): 1083-1087.

  52. Steardo L, Steardo L Jr, Zorec R, Verkhratsky A. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19. Acta Physiol (Oxf). 2020; 229 (3): e13473.

  53. Boesveldt S, Postma EM, Boak D, Welge-Luessen A, Schopf V, Mainland JD et al. Anosmia-a clinical review. Chem Senses. 2017; 42 (7): 513-523.

  54. Otte MS, Bork ML, Zimmermann PH, Klubmann JP, Luers JC. Patients with COVID-19-associated olfactory impairment also show impaired trigeminal function. Auris Nasus Larynx. 2021; S0385-8146(21)00221-2.

  55. Matta J, Wiernik E, Robineau O, Carrat F, Touvier M, Severi G et al. Association of self-reported COVID-19 infection and SARS-CoV-2 serology test results with persistent physical symptoms among french adults during the COVID-19 pandemic. JAMA Intern Med. 2022; 182 (1): 19-25.



EVIDENCE LEVEL

III




2020     |     www.medigraphic.com